Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

2.1 Atezolizumab (Tecentriq, Roche) is indicated for 'adjuvant treatment following complete resection for adult patients with stage II to IIIA (7^th edition of the UICC/AJCC-staging system) non-small-cell lung cancer (NSCLC) whose tumours have programmed cell death ligand-1 (PD‑L1) expression on ≥50% of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for atezolizumab.

2.3 The list price is £3,807.69 for a (1,200 mg) 20‑ml vial and £2,665.38 for a (840 mg) 14‑ml vial (excluding VAT; BNF online accessed July 2022).

2.4 The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.